EMD Serono, a subsidiary of Germany's Merck KGaA, has appointed Drew Young as senior vice president of neurology and immunology, where he will lead the strategic direction of the US neurology and immunology franchise. 2 September 2014
Belgian cell therapy company TiGenix has appointed Marie Paule Richard as chief medical officer, and Mary Carmen Diez as its vice president of medical affairs and new product commercialization. 1 September 2014
French drug major Sanofi has replaced its North American chief Anne Whitaker with Jez Moulding, who will be head of the region’s pharma business following a senior management role in Japan and Asia Pacific. 28 August 2014
Coming from her position as president of Sanofi’s North American pharma division, Anne Whitaker has been named chief executive of Synta Pharmaceuticals. 12 August 2014
Astellas Pharma EMEA, the regional headquarters of Japanese drug major Astellas Pharma, has appointed Simon Dew as chief strategy officer. 7 August 2014
Quebec-based cardiovascular drug development specialist Milestone Pharmaceuticals has announced the appointment of Francis Plat as chief medical officer. He is a cardiologist with extensive experience in cardio drug development. 21 July 2014
US-based Neurotrope, developers of diagnostic and therapeutic technologies for the treatment of neurodegenerative diseases, has announced the appointment of co-chairmen Charles Ramat and Paul Freiman as co-chief executives on an interim basis. 21 July 2014
US-based drug development and discovery company Aptuit has appointed Paul Overton as executive vice president, business development and marketing. He is now responsible for all of Aptuit’s sales and marketing activities. 16 July 2014
US-based clinical-stage biopharma company Xencor has announced the appointment of Kurt Gustafson to its board of directors. He will also serve as chair of the audit and compensation committees for the company which develops engineer monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. 15 July 2014
Merck Serono, the biotech unit of Germany’s Merck KGaA, has announced the appointment of Luciano Rossetti as executive vice president and global head of research and development. 14 July 2014
Taiwan-based pharmaceutical company ScinoPharm (TWSE: 1789) says that its president and chief executive will retire at the end of July after 17 years of service. He will be succeeded by Dr Yung-Fa (Fred) Chen, who is currently the company’s vice president of research and development, and chief technology officer, from August 1. 11 July 2014
US-based oncology specialist Jounce Therapeutics has announced the appointment of Richard Murray to chief executive officer. Dr Murray has more than 20 years of experience in building research and development capabilities in small startups and large pharmaceutical companies. He replaces the interim chief executive, Cary Pfeffer. 11 July 2014
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024